Skip to main content
Top
Published in: Medical Oncology 2/2011

01-06-2011 | Original Paper

Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation

Authors: Vallian Sadeq, Nassiri Isar, Tavassoli Manoochehr

Published in: Medical Oncology | Issue 2/2011

Login to get access

Abstract

PTEN/MMAC1/TEP1 encodes a tumor suppressor protein, which regulates cell cycle progression, translation, and apoptosis by blocking the activation of Akt/PKB. The loss of PTEN function increases cell survival and induces tumor invasion. In this study, PTEN promoter status and its correlation with genetic and pathologic parameters were analyzed in genomic DNA from Iranian patients with breast cancer. DNA methylation patterns in the CpG islands were determined by a methylation-specific PCR (MSP) assay. PTEN promoter methylation was found to be present in 37 of 53(70%) tumor tissues and none in 20 normal counterparts. Moreover, promoter methylation was found in patients with heterozygote mutation in the PTEN gene. The pathological history of cancerous tissue sections showed that PTEN gene could be inactivated at the stages III and IV in sporadic breast cancer. These findings suggested that promoter hypermethylation of PTEN might contribute to the progression of sporadic breast cancer in human.
Literature
1.
go back to reference Stambolic V, Suzuki A, Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.PubMedCrossRef Stambolic V, Suzuki A, Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.PubMedCrossRef
2.
go back to reference Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146:389–403.PubMedCrossRef Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146:389–403.PubMedCrossRef
3.
go back to reference Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3:117–30.PubMedCrossRef Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3:117–30.PubMedCrossRef
4.
go back to reference Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23:575–87.PubMedCrossRef Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23:575–87.PubMedCrossRef
5.
go back to reference Reifenberger J, Wolter M, Bostrom J, et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch. 2000;436:487–93.PubMedCrossRef Reifenberger J, Wolter M, Bostrom J, et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch. 2000;436:487–93.PubMedCrossRef
6.
go back to reference Piekarski JH, Biernat W. Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. Histopathology. 2006;49:248–55.PubMedCrossRef Piekarski JH, Biernat W. Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. Histopathology. 2006;49:248–55.PubMedCrossRef
7.
go back to reference Li Z, Wings TY, Chow LWC. PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer. Biomed Pharmacother. 2007;61:558–61.CrossRef Li Z, Wings TY, Chow LWC. PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer. Biomed Pharmacother. 2007;61:558–61.CrossRef
8.
go back to reference Mise-Omataa S, Obataa Y, Iwaseb S, Misec N, Doia T. Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells. Biochem Biophys Res. 2005;38:1034–42.CrossRef Mise-Omataa S, Obataa Y, Iwaseb S, Misec N, Doia T. Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells. Biochem Biophys Res. 2005;38:1034–42.CrossRef
9.
go back to reference Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten±mice. Cancer Res. 2000;60(13):3605–11.PubMed Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten±mice. Cancer Res. 2000;60(13):3605–11.PubMed
10.
go back to reference Nassiri I, Tavasoli M, Faghihi M. Pharmacogenomic profiling of the PI3 K/PTEN pathway in sporadic breast cancer. Iran Biomed J. 2008;12(4):209–14. Nassiri I, Tavasoli M, Faghihi M. Pharmacogenomic profiling of the PI3 K/PTEN pathway in sporadic breast cancer. Iran Biomed J. 2008;12(4):209–14.
11.
go back to reference Nassiri I, Tavasoli M, Faghihi M. Mutational analysis in the MMAC1 gene associated in patients with juvenile polyposis syndrome and cowden fisease. Austral Asian J Can. 2008;7(3):25–30. Nassiri I, Tavasoli M, Faghihi M. Mutational analysis in the MMAC1 gene associated in patients with juvenile polyposis syndrome and cowden fisease. Austral Asian J Can. 2008;7(3):25–30.
12.
go back to reference Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot. 1975;28:727–32.PubMed Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot. 1975;28:727–32.PubMed
13.
go back to reference Singer C, Köstler W, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochim Biophys Acta. 2008;1786(2):105–13.PubMed Singer C, Köstler W, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochim Biophys Acta. 2008;1786(2):105–13.PubMed
14.
go back to reference Sambrook J, Fritsh EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 2001. Sambrook J, Fritsh EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 2001.
15.
go back to reference Miller SA, Dykes DD, Polesky HF. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCrossRef Miller SA, Dykes DD, Polesky HF. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCrossRef
16.
go back to reference Zysman MA, Chapman WB, Bharati B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002;160:795–800.PubMedCrossRef Zysman MA, Chapman WB, Bharati B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002;160:795–800.PubMedCrossRef
18.
go back to reference Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002;33:405–9.PubMedCrossRef Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002;33:405–9.PubMedCrossRef
19.
go back to reference Khan K, Umagal K, Vora J, Bose N, Sehgal S, Koeffler E, et al. PTEN promoter is methylated in a proportion of invasive breast cancer. Int J Cancer. 2004;112:407–10.PubMedCrossRef Khan K, Umagal K, Vora J, Bose N, Sehgal S, Koeffler E, et al. PTEN promoter is methylated in a proportion of invasive breast cancer. Int J Cancer. 2004;112:407–10.PubMedCrossRef
20.
go back to reference Kang Y, Lee HS, Ho KW. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 2002;82:285–91.PubMed Kang Y, Lee HS, Ho KW. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 2002;82:285–91.PubMed
21.
go back to reference Chang S, Lee SN, Cho MS, Koo H, Han WS, Im SA, et al. Loss of PTEN expression in breast cancers. Korean J Path. 2005;39:236–41. Chang S, Lee SN, Cho MS, Koo H, Han WS, Im SA, et al. Loss of PTEN expression in breast cancers. Korean J Path. 2005;39:236–41.
Metadata
Title
Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation
Authors
Vallian Sadeq
Nassiri Isar
Tavassoli Manoochehr
Publication date
01-06-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9473-8

Other articles of this Issue 2/2011

Medical Oncology 2/2011 Go to the issue